JAK of all trades: Ruxolitinib as a new therapeutic option for CML patients. (2018)

First Author: Gallipoli P
Attributed to:  Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/j.leukres.2018.10.010

PubMed Identifier: 30392903

Publication URI: http://europepmc.org/abstract/MED/30392903

Type: Journal Article/Review

Volume: 75

Parent Publication: Leukemia research

ISSN: 0145-2126